Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities

Circulation. 2004 Aug 3;110(5):566-70. doi: 10.1161/01.CIR.0000137123.55051.9B. Epub 2004 Jul 19.

Abstract

Background: One third of cases of upper-extremity deep vein thrombosis (DVT) are primary, ie, they occur in the absence of central venous catheters or cancer. Risk factors for primary upper-extremity DVT are not well established, and the recurrence rate is unknown.

Methods and results: We studied 115 primary upper-extremity DVT patients and 797 healthy controls for the presence of thrombophilia due to factor V Leiden, prothrombin G20210A, antithrombin, protein C, protein S deficiency, and hyperhomocysteinemia. Transient risk factors for venous thromboembolism were recorded. Recurrent upper-extremity DVT was evaluated prospectively over a median of 5.1 years of follow-up. The adjusted odds ratio for upper-extremity DVT was 6.2 (95% CI 2.5 to 15.7) for factor V Leiden, 5.0 (95% CI 2.0 to 12.2) for prothrombin G20210A, and 4.9 (95% CI 1.1 to 22.0) for the anticoagulant protein deficiencies. Hyperhomocysteinemia and oral contraceptives were not associated with upper-extremity DVT. However, in women with factor V Leiden or prothrombin G20210A who were taking oral contraceptives, the odds ratio for upper-extremity DVT was increased up to 13.6 (95% CI 2.7 to 67.3). The recurrence rate was 4.4% patient-years in patients with thrombophilia and 1.6% patient-years in those without thrombophilia. The hazard ratio for recurrent upper-extremity DVT in patients with thrombophilia compared with those without was 2.7 (95% CI 0.7 to 9.8).

Conclusions: Inherited thrombophilia is associated with an increased risk of upper-extremity DVT. Oral contraceptives increase the risk only when combined with inherited thrombophilia. The recurrence rate of primary upper-extremity DVT is low but tends to be higher in patients with thrombophilia than in those without.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activated Protein C Resistance / complications
  • Activated Protein C Resistance / epidemiology
  • Activated Protein C Resistance / genetics
  • Adolescent
  • Adult
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome / complications
  • Antiphospholipid Syndrome / epidemiology
  • Antithrombin III Deficiency / complications
  • Antithrombin III Deficiency / epidemiology
  • Antithrombin III Deficiency / genetics
  • Arm / blood supply*
  • Cohort Studies
  • Contraceptives, Oral, Hormonal / adverse effects
  • Disease-Free Survival
  • Factor V / genetics
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperhomocysteinemia / complications
  • Hyperhomocysteinemia / epidemiology
  • Hyperhomocysteinemia / genetics
  • Life Tables
  • Male
  • Mass Screening
  • Middle Aged
  • Mutation
  • Prevalence
  • Protein S Deficiency / complications
  • Protein S Deficiency / epidemiology
  • Protein S Deficiency / genetics
  • Prothrombin / genetics
  • Recurrence
  • Risk Factors
  • Thrombophilia / chemically induced
  • Thrombophilia / complications
  • Thrombophilia / drug therapy
  • Thrombophilia / epidemiology
  • Thrombophilia / genetics
  • Venous Thrombosis / epidemiology*
  • Venous Thrombosis / etiology

Substances

  • Anticoagulants
  • Contraceptives, Oral, Hormonal
  • factor V Leiden
  • Factor V
  • Prothrombin